Law360, New York ( March 18, 2015, 1:36 PM EDT) -- In the past few years, the use of prescription drugs for off-label indications has created legal risk for many pharmaceutical companies. Between 2004 and 2010, the federal government collected $8 billion from 21 cases related to alleged off-label promotion.[1] The fundamental regulatory structure under which the pharmaceutical industry operates is one where a manufacturer may sell, but not actively promote, a drug for off-label use.[2]...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.